MedTrace Logo

Evaluation of Efficacy and Safety of Gynomax® XL Ovule

NCT03839875 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 116

Last updated 2020-01-31

No results posted yet for this study

Summary

Efficacy and safety of Gynomax® XL ovule in the treatment of trichomonal vaginitis, bacterial vaginosis, candidal vulvovaginitis and mixed vaginal infections will be evaluated in this open label, single-arm, multicentral study.

Conditions

  • Trichomonal Vaginitis
  • Bacterial Vaginosis
  • Candidal Vulvovaginitis
  • Mixed Vaginal Infections

Interventions

DRUG

Gynomax® XL Vaginal Ovule

tioconazole, tinidazole, lidocaine

Sponsors & Collaborators

  • Monitor CRO

    collaborator INDUSTRY

  • Exeltis Turkey

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-03
Primary Completion
2019-08-09
Completion
2019-08-09

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03839875 on ClinicalTrials.gov